Textor sells Crystal Palace stake to boost hopes of European competition
New York Jets owner Woody Johnson has agreed to buy John Textor's 43 percent stake in Crystal Palace in a deal that could boost the Eagles' hopes of playing in the Europa League next season.
The London club qualified for Europe for the first time in their history in May, beating Manchester City in the FA Cup final to win their first major trophy.
Advertisement
However, US businessman Textor has a majority stake in French side Lyon, who have also qualified for the Europa League.
Under UEFA multi-club ownership rules, it looked as though Palace would miss out because they finished lower in the Premier League (12th) than Lyon (6th) in Ligue 1 last season.
The BBC reported that Johnson, a former US ambassador to the United Kingdom, would pay £190 million ($255 million) for the shares.
"Crystal Palace Football Club can confirm that Robert Wood Johnson, 'Woody', an American businessman and co-owner of the New York Jets, has signed a legally binding contract to purchase Eagle Football's holding in the club," Palace said in a statement on Monday.
Advertisement
"Whilst the completion is pending approval from the Premier League and Women's Super League, we do not envisage any issues and look forward to welcoming Woody as a partner and director of the club."
Johnson, 78, is one of the heirs to the Johnson & Johnson pharmaceutical empire and had a net worth of $9.2 billion in 2024, according to the Bloomberg Billionaires Index.
In 2022 he missed out in a bid to buy Chelsea and is close to US President Donald Trump, under whom he served.
Textor, who also owns a significant stake in Brazilian side Botafogo, initially invested in Palace in 2021.
A decision by UEFA on Palace's participation in European competition is expected before the end of the month.
kca/jw/jc
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fast Company
38 minutes ago
- Fast Company
Hims & Hers stock plummets after Novo Nordisk ends partnership over 'knock-off' Wegovy
This morning, the Danish pharmaceutical giant Novo Nordisk announced the abrupt end of its brief partnership with telehealth company Hims & Hers Health, Inc. (NYSE: HIMS), citing concerns over Hims & Hers' 'knock-off' weight loss drugs. Now, Hims & Hers' shares are plummeting as investors react to the news. It's the latest update in a somewhat volatile year for Hims & Hers. Just this April, the company's stock spiked after it initially announced a collaboration with Novo Nordisk that allowed Hims & Hers to sell Novo Nordisk's FDA-approved weight loss drug, Wegovy, through its platform. But less than two months later, that partnership is fracturing after Novo Nordisk's claim that Hims & Hers engaged in 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.' At the time of this writing, HIMS stock is down 32.6% since market open. Here's what to know about the break-up: The shortage that fueled knock-off Wegovy Back in 2022, the Food and Drug Administration (FDA) declared a shortage of GLP-1 medications including Ozempic and Wegovy. Under this shortage notice, pharmacies were permitted to make compounded versions of the brand name drugs using their active ingredient, semaglutide, and sell them at a lower cost. Hims & Hers was one company that took part in selling a compounded—and non-FDA-approved—version of Wegovy. Then, this February, the FDA announced that Ozempic and Wegovy were no longer categorized under a shortage. With the brand name drugs fully back on the market, the FDA gave compounders 60 to 90 days to stop making copies of the patented drugs. At the time, Hims & Hers stated in a regulatory filing that, while it saw pathways to continue offering access to certain compounded GLP-1s after the shortage, it could not 'guarantee that we will be able to continue offering these products in the same manner, to the same extent, or at all.' However, an analyst told Reuters that Hims & Hers appeared poised to continue selling compounded semaglutide using 'personalized doses' after the shortage officially ended. Why is Novo Nordisk cutting ties now? In the wake of the FDA's shortage notice, Hims & Hers announced in April that it was entering a 'long-term collaboration' with Novo Nordisk to offer Wegovy directly to its consumers. Now, though, Novo Nordisk is breaking off the commitment over claims that Hims & Hers has not acted fast enough to stop selling its compounded GLP-1. Other telehealth companies, like Ro and Noom, have similarly faced criticism for continuing to sell their own compounded GLP-1 despite agreements with Eli Lilly, the maker of Zepbound. In an email to Fast Company, a Novo Nordisk spokesperson explained that 'semaglutide compounding is permitted under US compounding laws only in rare instances,' adding that other companies it's working with have 'demonstrated a good faith effort to transition patients to authentic, FDA-approved Wegovy.' However, the spokesperson continued, 'after over one month into the collaboration, Hims & Hers Health, Inc. has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that puts patient safety at risk. This is unacceptable and that is why we have decided to end the collaboration.' That personalization, involves offering the same drug; however, at different doses. In a press release published this morning, Novo Nordisk also noted that it is 'deeply concerned' about knock-off drugs 'made with foreign illicit active pharmaceutical ingredients.' 'Based on Novo Nordisk's investigation, the 'semaglutide' active pharmaceutical ingredients that are in the knock-off drugs sold by telehealth entities and compounding pharmacies are manufactured by foreign suppliers in China,' the release reads. 'According to a report from the Brookings Institute, FDA has never authorized or approved the manufacturing processes used by any of these foreign suppliers to make semaglutide, nor has FDA ever reviewed or authorized the quality of the 'semaglutide' they produce.' Hims & Hers did not immediately respond to Fast Company 's request for comment on Novo Nordisk's claims. On X, Novo Nordisk CEO Andrew Dudam said 'Novo Nordisk's commercial team increasingly pressured us to control clinical standards and steer patients to Wegovy regardless of whether it was clinically best for patients. We refuse to be strong-armed by any pharmaceutical company's anticompetitive demands that infringe on the independent decision making of providers and limit patient choice.' He went on to say 'We will continue to offer access to a range of treatments, including Wegovy, to ensure providers can serve the individual needs of patients.'
New York Times
42 minutes ago
- New York Times
Manchester City's Rico Lewis banned for three matches after Club World Cup red card
Rico Lewis will miss Manchester City's final Club World Cup group game and their last-16 tie after his three-match suspension for an opening day sending off was upheld. The 20-year-old was show a straight red card in City's opening win over Wydad which saw him miss Sunday's 6-0 victory against Al Ain, with the original one-match ban being extended to three matches. Advertisement City subsequently appealed the extended ban, but this was unsuccessful. Pep Guardiola's side must beat Juventus on Thursday to finish top of Group G of the Club World Cup, with the prospect of being tied with Real Madrid, should they win their group, in the first knockout round. Matheus Nunes started in the wing-back role in the last match as Guardiola trialled a back three. Lewis would have been in contention to start but it looks likely that the Portuguese midfielder will continue to deputise at right-back, which he did for the final months of last season. ()
Washington Post
an hour ago
- Washington Post
'Welcome to Wrexham' poster boy Paul Mullin leaves club on a season-long loan deal
WIGAN, England — Paul Mullin, the poster boy of a Wrexham team soaring through England's soccer leagues following its takeover by Hollywood celebrities, has left the club to join third-tier Wigan on a season-long loan deal. 'I'm excited for the next part of my story,' Mullin told Wigan's official website on Monday. 'I've scored a lot of goals over the last few years, but more than anything, I give my absolute all for the club that I'm playing for, and I'm going to do that again with Wigan.'
